Exozymes Inc. · NASDAQ:EXOZ
Exozymes — Investor Presentation (April 2026)
20 slides from Exozymes's investor presentation, Apr 1, 2026
Slide 1: Activating the Body's Master Metabolic Switch
Activating the Body’s Master Metabolic Switch Addressing multiple metabolic disorders through a single pathway April 1, 2026 powered by exclusive rights to eXoZymes’ breakthrough NCT cell-free biomanufacturing technology
Slide 2: We're on A Mission to Upgrade Health Span
THE BIG PICTURE We’re on A Mission to Upgrade Health Span Enabled by eXoZymes game changing cell-free biomanufacturing platform for breakthrough molecules The Game Changer We can manufacture things that are difficult to make, quickly and affordably eXoZymes creates better ways 1 Natural products are
Slide 3: A Global Epidemic is Exploding
THE METABOLIC HEALTH CRISIS A Global Epidemic is Exploding A GLOBAL EPIDEMIC IS EXPLODING Interconnected Chronic Diseases Diabetes Fatty Liver Disease Obesity (NAFLD) 1.2 Billion 800+ Million 2.5 Billion Fast growing chronic disease projected 2X by 2040 grown 2X since 1990 Conventional treatments st
Slide 4: Targeting the Root Cause of Declining Metabolic Health
UNDERSTANDING THE ROOT CAUSE UNDERSTANDING THE ROOT CAUSE Targeting the Root Cause of Declining Metabolic Health There is an energy crisis inside every cell Mitochondria are the energy Poor diet, chronic stress and sedentary Reduced cell function and powerhouses of every cell lifestyle disrupt mitoc
Slide 5: HNF4α – Activating a Mitochondria Master Control Switch
ADDRESSING THE ROOT CAUSE HNF4⍺ – Activating a Mitochondria Master Control Switch Restoring mitochondria is the key to transforming the way metabolic health is managed The Pathway Role in the Body Our Quest The Prize HNF4a The master Address previously Potentially the biggest metabolic switch undeve
Slide 6: NCT: First Potent Compound to Activate HNF4α
GROUNDBREAKING DISCOVERY NCT: First Potent Compound to Activate HNF4⍺ Promotes Wellness and addresses multiple interconnected disorders through a single pathway* NCT Fatty Liver Mitochondrial Gut Barrier Systemic Obesity Disease Dysfunction Breakdown Inflammation * This statement has not been evalua
Slide 7: Measurable Metabolic Results Without Diet Restriction
NCT PRE-CLINICAL TESTING Measurable Metabolic Results Without Diet Restriction Metabolic improvement through fatty acid oxidation DIO Mice on High Fat Diet 30-40% Body Weight Reduction Less weight gain on identical high-fat diet with equal caloric intake Mitochondrial Surge Significant increases in
Slide 8: NCT is Inaccessible via Conventional Chemistry
THE NCT BOTTLENECK NCT is Inaccessible via Conventional Chemistry The promise of NCT has remained locked <15 ppmNCT found in peppercorns Major Challenges to Overcome • NCT is nearly absent in nature with only trace amount available • Existing sources of NCT are mixtures of less potent natural analog
Slide 9: eXoZymes' Process Cracks the NCT Scale Barrier
THE COMMERCIAL BREAKTHROUGH eXoZymes’ Process Cracks the NCT Scale Barrier Concept to Pilot Scale in < 1 year + Successful Tech Transfer 99% Reaction Yield Industry-leading efficiency at pilot scale 6X Production Cycle Faster than conventional Concept to pilot-scale manufacturing approaches in < 1 y
Slide 10: eXoZymes Process Delivers High Quality NCT
DELIVERING HIGH QUALITY PRODUCT eXoZymes Process Delivers High Quality NCT Improves formulation performance and simplifies the product safety profile >99% Food/Pharma Grade Purity stronger and more predictable results in formulation High Purity NCT Reliable, high purity improves the regulatory journ
Slide 11: Super Clean Process Makes Scale-up Easy
THE EXOZYMES PROCESS ADVANTAGE Super Clean Process Makes Scale-up Easy Avoiding the unwanted by-products Conventional Methods eXoZymes NCT Example analysis Actual analysis (HPLC) (HPLC) Single product precision 11
Slide 12: Nature's Diversity, Scaled Like Chemistry
THE EXOZYMES ECONOMIC ADVANTAGE Nature’s Diversity, Scaled Like Chemistry No Living Systems Faster Production Time Simple Process Design No undesirable by-products More product output per Lower Capital Investment or seasonal variation installed capital Required More Reliable Lower Costs Better ROI 1
Slide 13: NCTX Targets Wellness and Therapeutic Metabolic Solutions
MARKET OPPORTUNITIES NCTX Targets Wellness and Therapeutic Metabolic Solutions Immediate Opportunity Longer Opportunity NUTRACEUTICALS PHARMACEUTICALS $100B+ Market $100B+ Market 13
Slide 14: Pure NCT by NCTX
NCTX NUTRACEUTICAL PRODUCT CONCEPT Pure NCT by NCTX Category Innovation: Moving Beyond Stimulants and Appetite Suppressants Metabolic Amplifier Supports Healthy Fat Metabolism Enhances the body's natural capacity to oxidize stored fats for fuel Complementary mechanism with GLP-1s offering metabolic
Slide 15: Fast market entry, asset-light growth for NCTX
COMMERCIALIZING NCT Fast market entry, asset-light growth for NCTX Driving NCT revenue growth through diversified channels Product Launch White Label B2B Ingredient Sales Production Ramp-up Develop compelling brand Ingredient access partnerships Co-branded “NCT by NCTX” License process tech to nar
Slide 16: Capital Light Expansion Strategy
FIVE YEAR SALES STRATEGY Capital Light Expansion Strategy Expand with CMOs to reach 6 million bottles without upfront CAPEX In 30 Capsule Bottles 2027 2028 2029 2030 Market Launch DTC Growth Boutique Retail Regional Retail Sales: ~200 K bottles Sales: ~2 million bottles Sales: 3.5 million bottles Sa
Slide 17: Roadmap: Launching NCTX Commercial Vehicle
LOOKING AHEAD Roadmap: Launching NCTX Commercial Vehicle 2026: eXoZymes NCT Accelerator Validated and Launch Ready Pilot Scale 100X Process + Optimization Integration Design Lock CMO Tech Transfer Composition IP Filed 2025 Q1 Q2 Q3 Q4 2027 Ferm, DSP, CFR, PIP Demonstrate target Human Use Studies Reg
Slide 18: Creating a Pharma Option
PATH AHEAD FOR PHARMA Creating a Pharma Option Aggressively acquiring metabolic innovation, particularly mechanisms that complement GLP-1s Leverage NCT Impact in Nutraceutical Market: HNF4⍺ Agonist Advance Clinical Program 2026 H2 2027 NCT Analogs / Formulations Optimized analogs with Cell Based Ass
Slide 19: Capital Focused on NCT Launch Readiness
USE OF PROCEEDS Capital Focused on NCT Launch Readiness Seed investment prepares NCT for Market Launch and Completes Initial Pharma Screen 2026 Use of Proceeds Total $4.5 Million NCT Supplements Initial Pharma Screen: $500K Tech Transfer - $3 M Supply Chain Qualification: $150K Regulatory: $250K Mar
Slide 20: Thank you
Thank you 20